Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

globenewswire.com
TLRY Tilray is mentioned as a key company in the Glioblastoma Multiforme market, indicating its involvement in the broader medical marijuana and oncology space, but no specific sentiment is attached to it in this context. IGC IGC Pharma is listed as a key company in the Alzheimer's Disease market, suggesting its involvement in the broader pharmaceutical landscape, but no specific sentiment is derived from this mention. JNJ Johnson & Johnson is mentioned as a key company in the Alzheimer's Disease market, indicating its presence in this therapeutic area, but no specific sentiment is associated with this mention. LLY Eli Lilly and Company is mentioned in the context of Alzheimer's Disease and Obstructive Sleep Apnea markets, indicating its broad involvement in healthcare but without specific sentiment. BMY Bristol Myers Squibb is listed as a key company in both the Alzheimer's Disease and Rheumatoid Arthritis markets, indicating its diversified presence in therapeutic areas but without specific sentiment. GSK GlaxoSmithKline is mentioned as a key company in the Rheumatoid Arthritis market, indicating its involvement in this therapeutic area, but no specific sentiment is derived from this mention. PFE Pfizer is listed as a key company in the Rheumatoid Arthritis market, indicating its presence in this therapeutic area, but no specific sentiment is associated with this mention. ABBV AbbVie is mentioned as a key company in the Rheumatoid Arthritis market, indicating its involvement in this therapeutic area, but no specific sentiment is derived from this mention.

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight New York, USA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

The medical marijuana competitive landscape report delivers important insights into approved as well as ongoing research of 65+ pipeline medical marijuana drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s Medical Marijuana Competitive Landscape 2026 report provides comprehensive global coverage of approved and pipeline medical marijuana therapies across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the medical marijuana domain.

Key Takeaways from the Medical Marijuana Pipeline Report

Request a sample and discover the recent developments in the medical marijuana treatment @ https://www.delveinsight.com/report-store/medical-marijuana-market

What is Medical Marijuana?

Medical marijuana, also known as medical cannabis, refers to cannabis and its active compounds, primarily cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD), used under medical supervision to help manage certain health conditions and symptoms. Depending on the formulation and condition, medical marijuana may be used to alleviate chronic pain, chemotherapy-related nausea and vomiting, muscle spasticity, and other symptoms. It is available in various forms, including oils, capsules, tablets, oral sprays, and dried cannabis, although approved products and permitted uses vary by country and region. Unlike recreational cannabis, medical marijuana is intended specifically for therapeutic purposes and is generally subject to medical and regulatory oversight.

To know more about medical marijuana, visit @ Medical Marijuana Therapies

Approved Medical Marijuana Drug Profile Analysis

Exilby: Vertanical

VER-01 (Exilby), developed by Vertanical, is a standardized full-spectrum Cannabis sativa extract that has emerged as Europe’s first approved medical cannabis-based treatment for chronic low back pain with a radicular (neuropathic) component. The therapy received marketing authorization in Germany in June 2026 after Phase III trials demonstrated significant reductions in pain, improvements in physical functioning and sleep, favorable tolerability, and no signs of dependence or withdrawal. Positioned as a first-in-class non-opioid analgesic, VER-01 provides a pharmaceutical-grade, standardized cannabinoid formulation as a potential alternative to opioids for chronic pain management. A pivotal Phase III trial evaluating the therapy in the United States is currently underway.

Syndros: Benuvia Therapeutics

Syndros is an orally administered liquid formulation containing dronabinol, a synthetic form of THC and a pharmaceutical cannabinoid. Dronabinol exerts complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been identified in neural tissues and are believed to contribute to the pharmacological effects of dronabinol. Syndros is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, as well as nausea and vomiting related to cancer chemotherapy in patients who have not responded adequately to conventional antiemetic therapies. Available as an oral solution, Syndros is the first and only FDA-approved dronabinol formulation in liquid oral form.

Find out more about what's the best pharma company offering medical marijuana medications @ Medical Marijuana Analysis

A snapshot of the Pipeline Medical Marijuana Drugs mentioned in the report:

Learn more about the emerging medical marijuana therapies @ Medical Marijuana Clinical Trials

As per Stuti Mahajan, Functional Head of Consulting at DelveInsight, the medical marijuana pipeline is characterized by ongoing research across multiple therapeutic areas, including pain, neurological disorders, inflammation, and psychiatric conditions. Current development efforts involve diverse products and formulations, reflecting the expanding clinical investigation of medical marijuana. Regulatory requirements, product standardization, and the availability of robust clinical evidence remain key factors influencing the development and progression of pipeline candidates.

Recent Developments in the Medical Marijuana Treatment Space

Scope of the Medical Marijuana Pipeline Report

Dive deep into rich insights for new medical marijuana for Alzheimer’s disease, visit @ Medical Marijuana Medications

Table of Contents

For further information on the medical marijuana pipeline therapeutics, reach out @ Medical Marijuana Therapeutics

Related Reports

Fragile X Syndrome Market

Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Fragile X syndrome companies, including Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.

Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Rheumatoid arthritis companies, including R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, SynAct Pharma, and others.

Obstructive Sleep Apnea Market

Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.

Glioblastoma Multiforme Market

Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GBM companies, including Avita Biomedical, TAE Life Sciences, Orbus Therapeutics, Chimerix, Laminar Pharma, Kazia Therapeutics, Precision NeuroMed, Imvax, Tilray, Medicinna Therapeutics, CNS Pharmaceuticals, Enterome, Northwest Biotherapeutics, Vigeo Therapeutics, VBI Vaccines, Immunomic Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.